Technology Opportunities

Refine / Revise Search41 technologies found
page 1 of 3
A Method in Improving Survival and Expansion of Hematopoietic Stem Cells (Yeda)
Summary hematopoietic cells. HSCs have the capacity to both self-renew and to differentiate, and they migrate from the bone marrow to the blood upon demand. Since HSCs can differentiate to a variety of cell types, including immune system cells, they have a huge therapeutic potential. Indeed, bone ...
Scientific Contact: Idit Shachar
More Details...
A Novel Approach for Controlling Gene Expression (Arbirtium - a Novel approach) (Yeda)
Summary One of the challenges in the areas of synthetic biology and its clinical applications, is the capacity to control the induction of different genes, whether for the purpose of activating genetic circuits or inducing the expression of a specific protein. Present approaches are limited to the ...
Scientific Contact: Rotem Sorek
More Details...
A Novel Approach for Treating Cancer and Collagen-Associated Diseases by Using Anti-LOXL-2 Antibody (Yeda)
Summary Disruption to the Extra-Cellular Matrix (ECM) is associated with many pathological conditions, such as various cancer types and tissue fibrosis, and also correlates with high tumor malignancy. Therefore, controlling ECM composition and morphology is considered a potential treatment for ...
Scientific Contact: Irit Sagi
More Details...
A Novel Method for Detecting Activation of Necroptosis via Exosome Analysis (Yeda)
Summary Numerous medical conditions are related to inflammation, such as pancreatitis, psoriasis, inflammatory bowel disease, atherosclerosis, neurodegeneration, and more. However, determination of inflammation in the body, especially at early stages of a pathology is difficult to assess. ...
Scientific Contact: David Wallach
More Details...
A Novel Method for Treating Drug-Resistant Lung Cancer Using a Combination of Antibodies (Yeda)
Summary A novel method for treating tyrosine kinase inhibitor (TKI)-resistant cancer, by using a combination of three different antibodies. Lung cancer is known as one of the most fatal forms of cancer. Notably, standard treatments for other cancer types (e.g. TKIs and mAbs), have shown only a ...
Scientific Contact: Yosef Yarden
More Details...
A Novel Method of Preventing or Treating Secondary Infections by Inhibition of Membrane Type I Matrix-Metalloproteinase-1 (Yeda)
Summary A novel method of preventing secondary infections, by inhibition of membrane type I matrix-metalloproteinase-1 (MT1-MMP), which reduces degradation of the extra-cellular matrix. Pathogens that infect the respiratory system are the cause of some of the most dangerous infections, especially ...
Scientific Contact: Irit Sagi
More Details...
A Novel Method of Treating Cancer by Targeting EGFR Ligand Amphiregulin (Yeda)
Summary A novel method for treating ovarian cancer by intercepting the EGFR ligand amphiregulin, when elevated expression levels are found in a patient. Ovarian cancer represents a relatively common type of cancer that affects women. However, the primary therapeutic option for ovarian cancer has ...
Scientific Contact: Yosef Yarden
More Details...
A Novel Technique to Produce Large Quantities of Therapeutic T cells (Yeda)
Summary Culturing and expanding T cells ex-vivo, while retaining their functionality, is an essential factor for the development of cutting-edge immunotherapies. A major problem frequently faced by physicians is the low number of T cells available for adoptive immunotherapy, and the difficulty to ...
Scientific Contact: Benjamin Geiger
More Details...
A TACE Inhibitor (ADAM17) (Yeda)
Summary New generation of superior nature-inspired therapeutics for treating inflammation.Inflammation is characterized by elevated levels of TNF-?. Neutralizing TNF-? activity was shown to be beneficial for patients with chronic autoimmune inflammatory diseases such as rheumatoid arthritis (RA) ...
Scientific Contact: Irit Sagi
More Details...
Affinity Maturated T-Cell Receptor (Yeda)
Summary However, a more efficacious and less toxic T cells based treatment is required. Effective therapy depends on the functional avidity between T cell receptors (TCRs) and peptide-MHC complex (pMHC). However the natural affinity of TCR is low and they do not naturally undergo the processes that ...
Scientific Contact: Lea Eisenbach
More Details...
Anti-QSOX1 Antibody for Treating Cancer and Metastasis (Yeda)
Summary A potential target for anticancer drug design.Cancer is the second leading cause of death in the US, accounting for roughly 23% of all deaths (as of 2008), and with estimated cost of care of $157 billion (as of 2010). Despite major advances in the management of cancer, most types of solid ...
Scientific Contact: Deborah Fass
More Details...
Antibodies Directed to ErbB Ligandsfor Treating Cancer (Yeda)
Summary < face="Times New Roman">A tailor-made strategy for cancer treatment. The ErbB family of tyrosine kinase receptors and their ligands play important roles in development and tissue remodeling throughout adulthood. ErbB proteins are involved in several types of human cancer. Clinical studies ...
Scientific Contact: Yosef Yarden
More Details...
Antibody Combinations in Treating Cancer (Yeda)
Summary Improved immunotherapy for breast cancer. Monoclonal antibodies (mAbs) to ErbB-2/HER2 growth factor receptor, or to its sibling, the epidermal growth factor receptor (EGFR), prolong survival of cancer patients, especially when combined with cytotoxic therapies. However, low effectiveness ...
Scientific Contact: Yosef Yarden
More Details...
Bioengineered Microorganisms that can "Eat" (Fix) CO2 (Yeda)
Summary Biomass production by plants and other photosynthetic organisms involves carbon fixation, the process of incorporating inorganic carbon dioxide into organic compounds. Currently carbon fixation by plants and other photosynthetic organisms is the limiting factor in biomass ...
Scientific Contact: Ron Milo
More Details...
Biological Treatment for Pancreatic Cancer (MMP7 mAb) (Yeda)
Summary The innovative concept leading to this high selectivity is immunization with both a synthetic metal-protein mimicry molecule, previously developed by the present inventors, followed by the metalloenzyme itself (e.g. MMP-7). The resulting antibody exhibits exceptional degree of specificity ...
Scientific Contact: Irit Sagi
More Details...
CD84 - a Novel Regulator of B-CLL Survival (Yeda)
Summary Chronic lymphocytic leukemia (CLL), a malignant disease characterized by the accumulation of B lymphocytes in the blood, lymphoid organs, and bone marrow, is the second most common type of leukemia in adults, accounting for about 7,000 new cases of leukemia each year. Presently, there is no ...
Scientific Contact: Idit Shachar
More Details...
Cholesterol Antibodies (Yeda)
Summary Description: Monoclonal antibodies specific for cholesterol/ceramide-rich domains (clones 405F, 14F, 499F) and cholesterol micro-domains (clones 36A1, 5881) in cell membranes.Originally raised against an artificial monolayer of lipid mixtures in, and were shown to specifically label the ...
Scientific Contact: Lia Addadi
More Details...
Disrupting or Preventing Formation of Biofilm by Enzyme Inhibitors (Yeda)
Summary Biofilm is a complex colony of bacteria, which are attached together by extracellular polymeric substance. This setting provides the bacteria protection against environmental factors, improves their surface attachment, and plays a major role in resistance to treatment. Therefore, biofilms ...
Scientific Contact: Ilana Kolodkin-Gal
More Details...
ERBB2 as a Novel Target to Treat Heart Failure by Inducing Cardiomyocyte Proliferation (Yeda)
Summary Existing treatments fail to compensate the irreversible loss of functional cardiomyocytes (CM), thus presenting a major medical unmet need. Inducing native CM replacement is one approach being tested as regenerative treatment, with the advantage of a more straightforward methodology over ...
Scientific Contact: Eldad Tzahor
More Details...
Fully Naive Induced Human Pluripotent Stem Cells (iPSC) (Yeda)
Summary A novel method to revert human iPSC to a fully naive state, retaining stable pluripotency. The feasibility for the existence of ground state naive pluripotency in human embryonic stem cells (hESC) has long been researched. This innovative technology supplies the composition of chemically ...
Scientific Contact: Jacob (Yaqub) Hanna
More Details...
ITTN's partners are affiliated with some of the world's leading Educational and Research Institutions.